Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Avastin’s Legacy May Be Quicker Withdrawal Process For New Approval Pathways

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

CBER Director Karen Midthun, who served as the FDA commissioner’s designee for the hearing on bevacizumab’s breast cancer claim, says the Avastin proceedings required “tremendous resources and time.” Consequently, any new drug approval route should include a mechanism for abbreviated withdrawal, she says.

You may also be interested in...



Not The Next Avastin? Plan For New ProAmatine Studies Would Negate Shire’s Withdrawal Hearing Request

A joint proposal from CDER and Shire calling for two new studies to verify clinical benefit of the hypotension agent would negate the need for a hearing on CDER’s proposed withdrawal, if Commissioner Hamburg accepts it.

Expedited Approval Pathway Concept Draws Strong Support But Different Proposals

Debate at a recent cancer research meeting reflects the challenges that lay ahead, and the diverging viewpoints that will have to be balanced, in creating any new approval mechanism.

Avastin Loses Its Breast Cancer Claim; FDA’s Hamburg Opts For Withdrawal Over Restrictions

FDA Commissioner Margaret Hamburg says Genentech has failed to identify a subpopulation of patients in whom the clinical benefits outweigh the risks. The company says it will not appeal the indication’s withdrawal but will pursue a new study in breast cancer.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS017586

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel